Adagene (ADAG) vs Oramed Pharmaceuticals (ORMP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Oramed Pharmaceuticals (ORMP) has outperformed Adagene (ADAG) over the past year, gaining 75.7% versus a gain of 42.2%. Over five years, ADAG leads with a -76.2% price change compared with -81.0% for ORMP. Adagene is the larger company by market cap ($186.7 million vs $174.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | ORMP |
|---|---|---|
| Share price | $2.78 | $4.20 |
| Market cap | $186.66M | $174.71M |
| 1-day change | -1.07% | -3.89% |
| YTD return | +47.09% | +47.37% |
| 1-year return | +42.20% | +75.73% |
| 5-year return | -76.24% | -80.96% |
| P/E ratio (TTM) | — | 1.02 |
| EPS (TTM) | $-0.37 | $4.13 |
| Dividend yield | 0.00% | 5.92% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.85 | $5.47 |
| 52-week low | $1.30 | $2.09 |
| Distance from 52-week high | -42.68% | -23.22% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +256.47% | +66.67% |
| Average volume | 244.76K | 190.50K |
| Shares outstanding | 67.14M | 41.60M |
| Employees | 128 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ORMP has outperformed ADAG by 33.5 percentage points over the past year.
- Oramed Pharmaceuticals offers a meaningfully higher dividend yield (5.92% vs 0.00%).
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Oramed Pharmaceuticals
ORMP stock →Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
Health Care · Biotechnology: Pharmaceutical Preparations
ADAG vs ORMP FAQ
Which is bigger, Adagene or Oramed Pharmaceuticals?
Adagene (ADAG) is larger, with a market capitalization of $186.66M compared with $174.71M for Oramed Pharmaceuticals (ORMP).
Which stock has performed better over the past year, ADAG or ORMP?
ORMP returned +75.73% over the past 12 months, compared with +42.20% for ADAG (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Adagene or Oramed Pharmaceuticals?
Oramed Pharmaceuticals pays a dividend yielding 5.92%, while Adagene does not currently pay a regular dividend.
Are Adagene and Oramed Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.